AURKC Promotes Clear Cell Renal Cell Carcinoma Proliferation Through Upregulation of ERp57

Overview

Journal J Cancer

Date 2025 Feb 3

PMID 39895780

Authors

Yan Liu

Yue Wen

Ziyuan Nie

Li Jia

Affiliations

Soon will be listed here.

Abstract

In recent years, aurora kinase C (AURKC) has emerged as a potential therapeutic target for cancer, having been found to induce proliferation in a variety of cancers. However, at present, its precise mechanism remains unclear. In this study, the specific role of AURKC in renal clear cell carcinoma and its mechanism was investigated. The protein expression levels of AURKC were evaluated in clear cell carcinoma and adjacent normal tissues, followed by prognostic analysis. Subsequently, cell models with knocked-down and overexpressed AURKC were constructed for cell experiments, and tumor-bearing mouse models were constructed to confirm the specific role of AURKC . AURKC was found to be highly expressed in ccRCC, which was associated with poor prognosis. In the experiments, the expression levels of CyclinD1 and proliferating cell nuclear antigen (PCNA) proteins were downregulated after AURKC knockdown, and the cell proliferation ability was found to decrease significantly. After AURKC overexpression, the levels of ERp57 protein expression increased significantly, also significantly enhancing the cell proliferation ability. In addition, AURKC was found to interact with ERp57 and exhibited a colocalization relationship. In the experiments, AURKC downregulation significantly inhibited the expression of ERp57 protein and blocked the growth of tumor tissue in tumor-bearing mice. These results suggest that the abnormal expression of AURKC in ccRCC enhances the expression of ERp57 protein, thereby promoting the proliferation of clear cell renal cell carcinoma. Thus, AURKC shows potential as a target for the treatment of ccRCC.

References

Chen L, Cai S, Wang J, Huai Y, Lu P, Chu Q . BRDT promotes ovarian cancer cell growth. Cell Death Dis. 2020; 11(11):1021. PMC: 7705741. DOI: 10.1038/s41419-020-03225-y. View

Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V . Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clin Cancer Res. 2012; 18(17):4621-32. DOI: 10.1158/1078-0432.CCR-11-2968. View

Al-Khafaji A, Marcus M, Davies M, Risk J, Shaw R, Field J . mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017; 13(6):4463-4468. PMC: 5452881. DOI: 10.3892/ol.2017.6012. View

Liao C, Wu T, Huang Y, Chang T, Wang C, Tsai M . Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 2011; 102(12):2255-63. DOI: 10.1111/j.1349-7006.2011.02102.x. View

Whitehurst A, Wilsbacher J, You Y, Luby-Phelps K, Moore M, Cobb M . ERK2 enters the nucleus by a carrier-independent mechanism. Proc Natl Acad Sci U S A. 2002; 99(11):7496-501. PMC: 124259. DOI: 10.1073/pnas.112495999. View

Rini B, Pal S, Escudier B, Atkins M, Hutson T, Porta C . Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2019; 21(1):95-104. DOI: 10.1016/S1470-2045(19)30735-1. View

Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z . Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner. Biochem Biophys Res Commun. 2015; 457(4):681-7. DOI: 10.1016/j.bbrc.2015.01.048. View

Zhu Y, Cai L, Guo J, Chen N, Yi X, Zhao Y . Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression. Tumour Biol. 2016; 37(10):14009-14023. DOI: 10.1007/s13277-016-5218-4. View

Tsou J, Chang K, Chang-Liao P, Yang S, Lee C, Chen Y . Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells. J Pathol. 2011; 225(2):243-54. DOI: 10.1002/path.2934. View

10.

Hettinghouse A, Liu R, Liu C . Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 2017; 181:34-48. PMC: 5743601. DOI: 10.1016/j.pharmthera.2017.07.011. View

11.

Dev Jr A, Vachher M, Prasad C . β-catenin inhibitors in cancer therapeutics: intricacies and way forward. Bioengineered. 2023; 14(1):2251696. PMC: 10478749. DOI: 10.1080/21655979.2023.2251696. View

12.

Fujiwara N, Friedman S, Goossens N, Hoshida Y . Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2017; 68(3):526-549. PMC: 5818315. DOI: 10.1016/j.jhep.2017.09.016. View

13.

Cicchillitti L, Di Michele M, Urbani A, Ferlini C, Donat M, Scambia G . Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res. 2009; 8(4):1902-12. DOI: 10.1021/pr800856b. View

14.

Strzalka W, Ziemienowicz A . Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2010; 107(7):1127-40. PMC: 3091797. DOI: 10.1093/aob/mcq243. View

15.

Qi Y, Wang D, Huang W, Wang B, Huang D, Xiong F . CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma. J Exp Clin Cancer Res. 2019; 38(1):413. PMC: 6781400. DOI: 10.1186/s13046-019-1415-5. View

16.

Liu Y, Wang J, Nie Z, Wen Y, Jia X, Zhang L . Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop. J Exp Clin Cancer Res. 2019; 38(1):439. PMC: 6864981. DOI: 10.1186/s13046-019-1453-z. View

17.

Rellmann Y, Dreier R . Different Forms of ER Stress in Chondrocytes Result in Short Stature Disorders and Degenerative Cartilage Diseases: New Insights by Cartilage-Specific ERp57 Knockout Mice. Oxid Med Cell Longev. 2019; 2018:8421394. PMC: 6311764. DOI: 10.1155/2018/8421394. View

18.

Walz A, Fernandez C, Geller J . Novel therapy for pediatric and adolescent kidney cancer. Cancer Metastasis Rev. 2019; 38(4):643-655. DOI: 10.1007/s10555-019-09822-4. View

19.

Bejar J, DiSanza Z, Quartuccio S . The oncogenic role of meiosis-specific Aurora kinase C in mitotic cells. Exp Cell Res. 2021; 407(2):112803. DOI: 10.1016/j.yexcr.2021.112803. View

20.

Carvajal R, Tse A, Schwartz G . Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006; 12(23):6869-75. DOI: 10.1158/1078-0432.CCR-06-1405. View